MX2019003569A - Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. - Google Patents

Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.

Info

Publication number
MX2019003569A
MX2019003569A MX2019003569A MX2019003569A MX2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A
Authority
MX
Mexico
Prior art keywords
bavituximab
methods
glycoprotein
levels
treatment
Prior art date
Application number
MX2019003569A
Other languages
English (en)
Spanish (es)
Inventor
Min Tang
Joseph S Shan
Steven W King
Connie Chang
Michael A Brown
Original Assignee
Oncologie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologie Inc filed Critical Oncologie Inc
Publication of MX2019003569A publication Critical patent/MX2019003569A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2019003569A 2016-09-27 2017-09-26 Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. MX2019003569A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662400589P 2016-09-27 2016-09-27
US201662406727P 2016-10-11 2016-10-11
US201762480994P 2017-04-03 2017-04-03
US201762507580P 2017-05-17 2017-05-17
PCT/US2017/053370 WO2018064013A1 (en) 2016-09-27 2017-09-26 METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR

Publications (1)

Publication Number Publication Date
MX2019003569A true MX2019003569A (es) 2020-07-22

Family

ID=66538296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003569A MX2019003569A (es) 2016-09-27 2017-09-26 Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.

Country Status (8)

Country Link
EP (1) EP3519827A1 (enExample)
JP (1) JP2019537619A (enExample)
KR (1) KR20190057303A (enExample)
CN (1) CN109863402A (enExample)
AU (1) AU2017334698A1 (enExample)
CA (1) CA3037008A1 (enExample)
MX (1) MX2019003569A (enExample)
WO (1) WO2018064013A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
US20200064353A1 (en) * 2018-08-13 2020-02-27 Regeneron Pharmaceuticals, Inc. Therapeutic Protein Selection in Simulated In Vivo Conditions
IL328607A (en) * 2020-05-12 2026-07-01 Astrazeneca Ab Methods and combinations for treating cancer using immune checkpoint inhibitor antibodies
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
CN114716547B (zh) * 2022-05-18 2023-11-21 珠海丽禾医疗诊断产品有限公司 一种包括抗原结合结构域的结合蛋白及其生产方法和应用
WO2024065243A1 (en) * 2022-09-28 2024-04-04 University Of Macau Drug for treatment of breast cancer and application thereof
CN119555937B (zh) * 2025-01-26 2025-05-20 杭州奥泰生物技术股份有限公司 一种犬虫媒病五联抗体检测卡及其制备方法和试剂盒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1096955B9 (en) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US7611704B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7906115B2 (en) 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
AU2012201537B2 (en) * 2002-07-15 2014-06-05 Board Of Regents, The University Of Texas System Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
US7572448B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7247303B2 (en) 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
CA2591914C (en) * 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP6156962B2 (ja) 2014-02-27 2017-07-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム エキソソームを単離するための方法および組成物
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途

Also Published As

Publication number Publication date
EP3519827A1 (en) 2019-08-07
KR20190057303A (ko) 2019-05-28
WO2018064013A9 (en) 2018-07-05
CN109863402A (zh) 2019-06-07
AU2017334698A1 (en) 2019-03-21
WO2018064013A1 (en) 2018-04-05
CA3037008A1 (en) 2018-04-05
JP2019537619A (ja) 2019-12-26
WO2018064013A8 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
CL2017002728A1 (es) Método para el tratamiento de cáncer
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
CO2017010618A2 (es) Anticuerpos contra icos
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
DOP2019000019A (es) Metodos para tratar el cancer de prostata
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
MX2017013178A (es) Terapia de combinacion para cancer.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
CL2020001936A1 (es) Métodos para el tratamiento de la atrofía muscular espinal.
MX2017005553A (es) Terapia de combinacion para cancer.
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2018000598A (es) Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
MX2019006332A (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.